Adult‐onset still’s disease and treatment results with tocilizumab
Adult‐onset Still's disease (AOSD) is a rare and non‐familial auto‐inflammatory disorder. Increased levels of IL‐6 and other pro‐inflammatory cytokines have been shown in AOSD. To evaluate the efficacy and safety profile of tocilizumab (TCZ), an IL‐6 receptor antagonist monoclonal antibody, in AOSD.